Publications

Mosquera JMiguel, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir, iv R et al..  2013.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.. Neoplasia. 15(1):1-10.

Gayvert KM, Dardenne E, Cheung C, Boland MRegina, Lorberbaum T, Wanjala J, Chen Y, Rubin MA, Tatonetti NP, Rickman DS et al..  2016.  A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors.. Cell Rep. 15(11):2348-56.

Rubin MA, Maher CA, Chinnaiyan AM.  2011.  Common gene rearrangements in prostate cancer.. J Clin Oncol. 29(27):3659-68.

Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, rosenberg jonathan, Mosquera JMiguel, Robinson B, Elemento O et al..  2016.  Clonal evolution of chemotherapy-resistant urothelial carcinoma.. Nat Genet. 48(12):1490-1499.

Fontugne J, Davis K, Palanisamy N, Udager A, Mehra R, McDaniel AS, Siddiqui J, Rubin MA, Mosquera JMiguel, Tomlins SA.  2016.  Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.. Mod Pathol. 29(2):157-65.

Feng FY, de Bono JS, Rubin MA, Knudsen KE.  2015.  Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function.. Mol Cell. 58(6):925-34.

Mosquera J-M, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G et al..  2008.  Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.. Clin Cancer Res. 14(11):3380-5.

D'Alfonso TM, Subramaniyam S, Ginter PS, Mosquera JMiguel, MacDonald TY, Noorzad Z, Orta LY, Liu Y-F, Rubin MA, Shin SJ.  2016.  Characterization of the leiomyomatous variant of myofibroblastoma: a rare subset distinct from other smooth muscle tumors of the breast.. Hum Pathol.

Rubin MA, Elemento O, Sboner A, Imielinski M, Pisapia D, Fernandes H, Zia H, Huang L, Tavassoli P, Kluk M.  2016.  The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretation. JAMIA.

Rubin MA, Chinnaiyan AM.  2006.  Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer.. Lab Invest. 86(11):1099-102.

Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM.  2012.  Beyond PSA: the next generation of prostate cancer biomarkers.. Sci Transl Med. 4(127):127rv3.

Mertz KD, Demichelis F, Kim R, Schraml P, Storz M, Diener P-A, Moch H, Rubin MA.  2007.  Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer.. Hum Pathol. 38(10):1454-62.

Mertz KD, Demichelis F, Sboner A, Hirsch MS, Dal Cin P, Struckmann K, Storz M, Scherrer S, Schmid DM, Strebel RT et al..  2008.  Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer.. Int J Cancer. 123(3):569-76.

Park K, Tomlins SA, Mudaliar KM, Chiu Y-L, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T et al..  2010.  Antibody-based detection of ERG rearrangement-positive prostate cancer.. Neoplasia. 12(7):590-8.

Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA et al..  2004.  Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.. Cancer Res. 64(24):9209-16.